IMS CORE lab teams up with Cristal Therapeutics
Cristal Therapeutics has announced that it has secured a Horizon 2020 grant. This allows the company to further develop the CriPec Nanomedicine Platform. This will be done in collaboration with the IMS CORE lab at Maastricht University’s M4I Division of Imaging Mass Spectrometry.
Cristal Therapeutics is a phase 2 clinical-stage pharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases. The ICARUS project will be carried out in close collaboration with the IMS CORE lab at the division of Imaging Mass Spectrometry, where CriPec® nanoparticle microlocalisation and drug release in tumours will be evaluated. Mass spectrometry imaging, technology together with Cristal Therapeutics’ expert team, will provide critical new insights to optimally design CriPec® nanomedicines with the aim of achieve superior therapeutic profiles.
The project at M4I will be led by Dr. Berta Cillero Pastor and by Prof. Ron Heeren.
For more details, read the full article on the Cristal Therapeutics website: http://cristaltherapeutics.com/cristal-therapeutics-awarded-horizon-2020-grant-to-further-develop-the-cripec-nanomedicine-platform/
Also read
-
Let it flow: What flowing blood tells us about blood clotting
Amaury Monard uses the Maastricht Flow Chamber to visualise blood clotting to see more precisely where things go wrong in patients.
-
Congratulations: NWO-XS Funding for "Trojan Horses in the Womb"
Theo de Kok, Houman Kahroba and Julian Krauskopf from the department of Translational Genomics have been awarded an NWO-XS grant for their project "Trojan Horses in the Womb: Small Extracellular Vesicles as Carriers of Air Pollution to the Fetal Brain."
-
Photos festive education meeting 2026
Photos festive education meeting 2026
